Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

CCR4 receptor antagonist

DRUG CLASS:

CCR4 receptor antagonist

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

mogamulizumab-kpkc (9)

mogamulizumab-kpkc (9)

›

No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	mogamulizumab-kpkc Sensitive: A2 - Guideline mogamulizumab-kpkc Sensitive : A2	mogamulizumab-kpkc Sensitive: A2 - Guideline mogamulizumab-kpkc Sensitive : A2
CCR4 positive	Leukemia	CCR4 positive	Leukemia	mogamulizumab-kpkc Sensitive: C2 – Inclusion Criteria mogamulizumab-kpkc Sensitive : C2	mogamulizumab-kpkc Sensitive: C2 – Inclusion Criteria mogamulizumab-kpkc Sensitive : C2
CCR4 positive	Lymphoma	CCR4 positive	Lymphoma	mogamulizumab-kpkc Sensitive: C2 – Inclusion Criteria mogamulizumab-kpkc Sensitive : C2	mogamulizumab-kpkc Sensitive: C2 – Inclusion Criteria mogamulizumab-kpkc Sensitive : C2
CCR4 negative	Solid Tumor	CCR4 negative	Solid Tumor	mogamulizumab-kpkc Sensitive: C2 – Inclusion Criteria mogamulizumab-kpkc Sensitive : C2	mogamulizumab-kpkc Sensitive: C2 – Inclusion Criteria mogamulizumab-kpkc Sensitive : C2
CCR4 overexpression	Head and Neck Cancer	CCR4 overexpression	Head and Neck Cancer	FLX475 Sensitive: C3 – Early Trials FLX475 Sensitive : C3	FLX475 Sensitive: C3 – Early Trials FLX475 Sensitive : C3
CCR4 overexpression	Head and Neck Cancer	CCR4 overexpression	Head and Neck Cancer	pembrolizumab + FLX475 Sensitive: C3 – Early Trials pembrolizumab + FLX475 Sensitive : C3	pembrolizumab + FLX475 Sensitive: C3 – Early Trials pembrolizumab + FLX475 Sensitive : C3
CCR4 overexpression	Nasopharyngeal Carcinoma	CCR4 overexpression	Nasopharyngeal Carcinoma	FLX475 Sensitive: C3 – Early Trials FLX475 Sensitive : C3	FLX475 Sensitive: C3 – Early Trials FLX475 Sensitive : C3
CCR4 overexpression	Nasopharyngeal Carcinoma	CCR4 overexpression	Nasopharyngeal Carcinoma	pembrolizumab + FLX475 Sensitive: C3 – Early Trials pembrolizumab + FLX475 Sensitive : C3	pembrolizumab + FLX475 Sensitive: C3 – Early Trials pembrolizumab + FLX475 Sensitive : C3
CCR4 overexpression	Lymphoma	CCR4 overexpression	Lymphoma	FLX475 Sensitive: C3 – Early Trials FLX475 Sensitive : C3	FLX475 Sensitive: C3 – Early Trials FLX475 Sensitive : C3
HGF-L	T Acute Lymphoblastic Leukemia	HGF-L	T Acute Lymphoblastic Leukemia	mogamulizumab-kpkc Resistant: C3 – Early Trials mogamulizumab-kpkc Resistant : C3	mogamulizumab-kpkc Resistant: C3 – Early Trials mogamulizumab-kpkc Resistant : C3
CD28 overexpression	Lymphoma	CD28 overexpression	Lymphoma	mogamulizumab-kpkc Resistant: C3 – Early Trials mogamulizumab-kpkc Resistant : C3	mogamulizumab-kpkc Resistant: C3 – Early Trials mogamulizumab-kpkc Resistant : C3
CD28 overexpression	Leukemia	CD28 overexpression	Leukemia	mogamulizumab-kpkc Resistant: C3 – Early Trials mogamulizumab-kpkc Resistant : C3	mogamulizumab-kpkc Resistant: C3 – Early Trials mogamulizumab-kpkc Resistant : C3
CCR4 negative	Esophageal Cancer	CCR4 negative	Esophageal Cancer	mogamulizumab-kpkc Sensitive: C3 – Early Trials mogamulizumab-kpkc Sensitive : C3	mogamulizumab-kpkc Sensitive: C3 – Early Trials mogamulizumab-kpkc Sensitive : C3
CCR4 negative	Lung Cancer	CCR4 negative	Lung Cancer	mogamulizumab-kpkc Sensitive: C3 – Early Trials mogamulizumab-kpkc Sensitive : C3	mogamulizumab-kpkc Sensitive: C3 – Early Trials mogamulizumab-kpkc Sensitive : C3